The historical rank and industry rank for Genomma Lab InternacionalB de CV's Equity-to-Asset or its related term are showing as below:
MEX:LABB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38 Med: 0.46 Max: 0.52
Current: 0.47
During the past 13 years, the highest Equity to Asset Ratio of Genomma Lab InternacionalB de CV was 0.52. The lowest was 0.38. And the median was 0.46.
MEX:LABB's Equity-to-Asset is ranked worse than 69.18% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs MEX:LABB: 0.47
Genomma Lab InternacionalB de CV (MEX:LABB) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Genomma Lab InternacionalB de CV Equity-to-Asset Related Terms
Genomma Lab InternacionalB de CV Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Equity-to-Asset Chart
MEX:LABB vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Equity-to-Asset falls into.
Genomma Lab InternacionalB de CV Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV (MEX:LABB) has a Equity-to-Asset of 0.47 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is near median its historical median of 0.46. Over the past decade, Genomma Lab InternacionalB de CV's Equity-to-Asset has ranged from 0.38 to 0.52. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #696 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 69.2%.
Is Genomma Lab InternacionalB de CV's Equity-to-Asset too high?
Genomma Lab InternacionalB de CV's current Equity-to-Asset of 0.47 is near median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 0.52. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Genomma Lab InternacionalB de CV's value of 0.47 is 23% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #696 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #696 out of 1006 companies for Equity-to-Asset. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Genomma Lab InternacionalB de CV's value of 0.47 is 23% below this benchmark. Historically, Genomma Lab InternacionalB de CV's own Equity-to-Asset has ranged from 0.38 to 0.52 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 0.61, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Equity-to-Asset of 0.47 is 23% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Equity-to-Asset is 0.47, which is near median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.67, compared to a current price of MXN15.34 — trading 13.2% below its estimated fair value. The current Equity-to-Asset is 0.47, which is near median its 10-year median of 0.46 and 23% below the Drug Manufacturers industry median of 0.61. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Equity-to-Asset is 0.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.34 is trading 13.2% below its estimated GF Value™ of MXN17.67.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Equity-to-Asset: 0.47 (near median its 10-year median of 0.46)
GF Value™: MXN17.67 vs. price of MXN15.34 (13.2% below fair value)
Industry Position: 23% below the Drug Manufacturers median (#696 of 1006)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
